2010
PrEP
_edited_edited_edited_edited.png)
Curators' Team
On November 23, 2010, researchers published the results of the iPrEx trial in The New England Journal of Medicine. The study, coordinated by the Gladstone Institutes, followed 2,499 gay and bisexual men and transgender women in six countries, half of whom took a daily pill combining two HIV drugs, emtricitabine and tenofovir, while the other half took a placebo. The pill reduced the risk of HIV infection by about 44 percent overall, and by about 73 percent among those who took it on at least 90 percent of days; 36 people taking the pill became infected, compared with 64 taking the placebo. It…
LOADING...
PrEP
_edited.png)
ADDED BY:
Curators' Team
.png)
.png)
Added By
Added By
Item Year
Item Year
Year Added
Item Year
Source
Item Year
Location
Item Year
LIVE LOUD
On November 23, 2010, researchers published the results of the iPrEx trial in The New England Journal of Medicine. The study, coordinated by the Gladstone Institutes, followed 2,499 gay and bisexual men and transgender women in six countries, half of whom took a daily pill combining two HIV drugs, emtricitabine and tenofovir, while the other half took a placebo. The pill reduced the risk of HIV infection by about 44 percent overall, and by about 73 percent among those who took it on at least 90 percent of days; 36 people taking the pill became…
Keep up with history
in the making.
Plus, get invited to curate, including telling
your own stories, and receive new product alerts and priority collab opportunities.
Customize preferences.
Added By
Added By
Item Year
Added By
Year Added
Added By
Location
Added By
Source
Added By
Item Year
Item Year
ITEM YEAR
2010
Year Added
2026
Source
NEJM
Location
San Francisco, CA
LOCATION
Item Year
ITEM YEAR
Item Year
ITEM YEAR
Item Year
YEAR ADDED
Item Year
SOURCE
Item Year
LOCATION
Item Year
SOURCE
Item Year
YEAR ADDED
Item Year
ADDED BY
Item Year
ADDED BY
Item Year
2010
ITEM YEAR
ADDED BY
Item Year
PrEP
On November 23, 2010, researchers published the results of the iPrEx trial in The New England Journal of Medicine. The study, coordinated by the Gladstone Institutes, followed 2,499 gay and bisexual men and transgender women in six countries, half of whom took a daily pill combining two HIV drugs, emtricitabine and tenofovir, while the other half took a placebo. The pill reduced the risk of HIV infection by about 44 percent overall, and by about 73 percent among those who took it on at least 90 percent of days; 36 people taking the pill became infected, compared with 64 taking the placebo. It was the first study to show that pre exposure prophylaxis, PrEP, could reduce HIV risk in people.
Tenofovir, one of the two drugs in the pill, was developed by Gilead Sciences from antiviral research at the Institute of Organic Chemistry and Biochemistry in Prague. It was approved to treat HIV on October 26, 2001, and in August 2004 Gilead combined it…